Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2005

View Archived Issues

Promising results with oral FXa inhibitor BAY-59-7939 reported at ISTH meeting

SB-497115 increases platelet counts in healthy volunteers

Pfizer makes strides in Q2

Speedel boosts pipeline development with private funding round

Neose Technologies to restructure operations

GlycoGenesis lays out plans for development of GCS-100

Novel NHE-1 inhibitor demonstrates preclinical cardioprotection

NCX-6550 elicits superior antithrombosis and antiatherogenesis effects

Tarceva sNDA for pancreatic cancer to be reviewed in September

Tysabri safety evaluation update

First melanoma patients complete treatment in phase I study of PV-10

Neurocrine Biosciences presents data on CRF-1 antagonist NBI-35965

Positive findings for bosentan in systemic sclerosis patients

Further investigation of orally active FXa inhibitor razaxaban

Dosing completed in phase II study of HepeX-B

European authorities approve phase III studies of Japanese encephalitis vaccine

BCX-4208 enters phase Ib study

Fodosine begins phase I pharmacokinetic study

NexMed updates status of lead programs

Update on tacrolimus ointment in the treatment of atopic dermatitis

Promising results reported for TRX-4 in type 1 diabetes

Recent patents cover novel antidepressants

Recent patents cover novel treatments for neurological disorders

Prodrug SERMs prepared and tested at GlaxoSmithKline

Novel therapeutics for cardiovascular diseases reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...